Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding
- 1 May 2010
- journal article
- review article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 16 (5) , 881-895
Abstract
The aim of this article is to critically review available data regarding the safety of immunomodulators and biological therapies during pregnancy andKeywords
This publication has 116 references indexed in Scilit:
- A 24-Year-Old Pregnant Woman With Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2009
- Absence of Infliximab in Infants and Breast Milk From Nursing Mothers Receiving Therapy for Crohn's Disease Before and After DeliveryJournal of Clinical Gastroenterology, 2009
- Inflammatory bowel disease in pregnancyBMJ, 2008
- Review article: use of antitumour necrosis factor therapy in inflammatory bowel disease during pregnancy and conceptionAlimentary Pharmacology & Therapeutics, 2008
- Cyclosporin A treatment of steroid-refractory ulcerative colitis during pregnancy: report of two cases: Figure 1Gut, 2007
- The Successful Use of Adalimumab to Treat Active Crohn's Disease of an Ileoanal Pouch During PregnancyDigestive Diseases and Sciences, 2006
- Fertility and pregnancy in the patient with inflammatory bowel diseaseGut, 2006
- Exposure to thiopurine drugs through breast milk is low based on metabolite concentrations in mother‐infant pairsBritish Journal of Clinical Pharmacology, 2006
- Outcome of Pregnancy in Women Receiving Infliximab for the Treatment of Crohn's Disease and Rheumatoid ArthritisAmerican Journal of Gastroenterology, 2004
- Infliximab treatment and pregnancy outcome in active Crohn's diseaseAmerican Journal of Gastroenterology, 2001